Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant
Authors:
- 1 November 1997
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 273 (5) , E965-E971
Abstract
To investigate the role of increased polyol pathway activity and hemodynamic deficits in the pathogenesis of diabetic retinopathy in non-insulin-dependent diabetes mellitus (NIDDM), Otsuka Long-Evans Tokushima fatty (OLETF) rats, an animal model of human NIDDM, were given water with or without 30% sucrose and some of them were fed laboratory chow containing 0.03% cilostazol, an anticoagulant, or 0.05% [5-(3-thienyl)tetrazol-1-yl] acetic acid monohydrate (TAT), an aldose reductase inhibitor, for 8 wk. Long-Evans Tokushima Otsuka (LETO) rats were used as nondiabetic controls. The peak latencies of oscillatory potentials of the electroretinogram in sucrose-fed OLETF rats were significantly prolonged compared with those in OLETF rats without sucrose feeding and LETO rats. There was a marked increase in platelet aggregability and a significant decrease in erythrocyte 2,3-diphosphoglycerate in sucrose-fed OLETF rats. Cilostazol significantly improved these parameters without changes in retinal levels of sorbitol and fructose. TAT, however, ameliorated all of these parameters. These findings confirm that the sucrose-fed OLETF rat is a useful animal model of retinopathy in human NIDDM and suggest that cilostazol improved diabetic retinopathy by modifying vascular factors, not by altering polyol pathway activity.Keywords
This publication has 26 references indexed in Scilit:
- Diabetic neuropathy in sucrose-fed otsuka long-evans tokushima fatty rats: Effect of an aldose reductase inhibitor, TATLife Sciences, 1997
- Nerve function and blood flow in Otsuka Long-Evans Tokushima Fatty rats with sucrose feeding: effect of an anticoagulantEuropean Journal of Pharmacology, 1996
- An aldose reductase inhibitor, TAT, prevents electroretinographic abnormalities and ADP‐induced hyperaggregabiIity in streptozotocin‐induced diabetic ratsEuropean Journal of Clinical Investigation, 1995
- CilostazolCardiovascular Drug Reviews, 1993
- Potential Therapeutic Approaches to the Treatment or Prevention of Diabetic Neuropathy: Evidence from Experimental StudiesDiabetic Medicine, 1993
- Aldose Reductase Inhibition Restores Endothelial Cell Function in Diabetic Rabbit AortaJournal of Cardiovascular Pharmacology, 1993
- The development of electroretinogram abnormalities and the possible role of polyol pathway activity in diabetic hyperglycemia and galactosemiaMetabolism, 1988
- Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy.Journal of Clinical Investigation, 1988
- Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats.Journal of Clinical Investigation, 1985
- Ultrastructural alterations during the development of retinopathy in sucrose-fed and streptozotocin-diabetic ratsExperimental Eye Research, 1977